Tildrakizumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), NICE (England) and SMC (Scotland), among others, recommended or restricted tildrakizumab, while NYE METODER (Norway) did not recommend it.
Assessment has run over 8 years, from 2018 at PBAC (Australia) to 2026 at PBAC (Australia).
CIPM (Spain) changed its position: not recommended on 27 Oct 2022, recommended by 11 May 2023, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 5 of 17 records date from 2023 or later.
3 distinct indication wordings are recorded for tildrakizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 17 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess tildrakizumab, in 2018; TLV (Sweden) did not open a file until 21 Nov 2022 — a wide spread of 4.3 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 6 years in total.
3 of the 10 agencies here assessed tildrakizumab more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for tildrakizumab.
The full ledger for tildrakizumab reads 8 recommended, 4 not recommended, 3 restricted and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2023 | Severe chronic plaque psoriasis (CPP) | Not Recommended | source |
| CIPM (Spain) | 11 May 2023 | Indicación terapéutica autorizada: Ilumetri está indicado para el tratamiento de la psoriasis en placas de moderada a gr… | financed by the SNS · art. 92 e | source |
| HAS (France) | 10 May 2023 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| TLV (Sweden) | 21 Nov 2022 | Ilumetri ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| NYE METODER (Norway) | 17 Oct 2022 | Behandling av moderat til alvorlig plakkpsoriasis | not introduced | source |
12 further decisions for tildrakizumab, across 8 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 9 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 17 decisions for tildrakizumab from 10 agencies, 2018 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.